ReviewCommunications medicine2026
Microplastics as both a driver of genitourinary cancers and a deliverer of treatments.
Review in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microplastics and Nanoplastics in the Human Diet: Sources of Exposure, Bioavailability, Toxicokinetics, and Systemic Health Effects.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microplastics and nanoplastics (MNPs) are environmental contaminants increasingly detected in human tissues, raising public health concerns. Although evidence is still insufficient to directly link MNPs to genitourinary cancers (GU), this Review examines their potential role in prostate, bladder, and renal cell carcinoma. Proposed mechanisms include chronic inflammation, oxidative stress, genotoxicity, and endocrine disruption driven by plastic-associated additives. Emerging studies report quantitative detection of MNPs within human prostate and bladder tumors, with higher burdens associated with dietary habits such as frequent take-out food consumption. The Review also highlights their role in cancer therapy: MNPs may alter antineoplastic drug pharmacokinetics and promote resistance, yet polymer-based nanoparticles can be engineered as advanced drug delivery platforms. Materials such as PLGA and PEG may improve targeted delivery of chemotherapies and immunotherapies, supporting more effective and personalized treatment strategies in GU oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.